ProtAffin Gets €14M for Engineered Chemokines
BioWorld International Correspondent
ProtAffin AG raised €14 million (US$18.3 million) in a Series B round to progress its early stage pipeline of novel, protein-based therapeutics that act by disrupting biological signaling between extracellular glycan structures and their protein ligands.
The Graz, Austria-based company is adding 11 new staff on the strength of the new funding, boosting total headcount to 27 people.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST